Lutz D
I. Internen Abteilung, Krankenhauses der Elisabethinen, Linz.
Wien Med Wochenschr. 1993;143(16-17):416-9.
In 1983 was for the first time reported that natural interferon-alpha (IFN-alpha) has a cytoreductive effect when used for treatment of chronic myelogenic leukemia (CML). The following studies using natural as well as recombinant IFN-alpha preparations confirmed the high remission rates with this therapy (70% CR and more than 30% cytogenetic responses) in patients with CML. Flu-like symptoms are recorded in more than 90% of the patients in the initial therapy phase. IFN-alpha seems to have no activity in patients in accelerated phase or blast crisis. High doses of IFN, i.e. more than 4,000,000 per day, achieve high response rates. Responses correlate with risk factors. New possibilities for improvement of therapy results with IFN are the combinations of IFN with other therapy modalities or concepts such as chemotherapy and/or bone marrow transplantation.
1983年首次报道，天然α干扰素（IFN-α）用于治疗慢性粒细胞白血病（CML）时具有细胞减灭作用。随后使用天然及重组IFN-α制剂的研究证实，该疗法在CML患者中具有较高的缓解率（70%完全缓解及超过30%细胞遗传学反应）。在初始治疗阶段，超过90%的患者记录有流感样症状。IFN-α似乎对加速期或急变期患者无活性。高剂量IFN，即每天超过400万单位，可获得高反应率。反应与危险因素相关。IFN联合其他治疗方式或理念如化疗和/或骨髓移植是改善治疗效果的新途径。
